Insider Selling: Guardant Health Inc (NASDAQ:GH) Chairman Sells $10,017,000.00 in Stock
Guardant Health Inc (NASDAQ:GH) Chairman Amirali Talasaz sold 100,000 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $100.17, for a total transaction of $10,017,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
GH opened at $98.62 on Friday. The firm has a market cap of $9.17 billion and a price-to-earnings ratio of -35.22. Guardant Health Inc has a fifty-two week low of $27.04 and a fifty-two week high of $112.21. The company’s 50-day moving average price is $94.54 and its 200 day moving average price is $77.82.
Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.21. The firm had revenue of $53.98 million for the quarter, compared to analyst estimates of $35.97 million. Guardant Health had a negative net margin of 60.08% and a negative return on equity of 22.93%. Guardant Health’s quarterly revenue was up 178.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.75) earnings per share. Equities analysts anticipate that Guardant Health Inc will post -1.27 EPS for the current year.
A number of equities research analysts have recently issued reports on the stock. Cowen set a $110.00 target price on shares of Guardant Health and gave the company a “buy” rating in a research note on Wednesday, August 7th. Zacks Investment Research lowered shares of Guardant Health from a “strong-buy” rating to a “hold” rating in a research note on Saturday, August 10th. JPMorgan Chase & Co. increased their price objective on shares of Guardant Health from $90.00 to $135.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $125.00 price objective (up previously from $96.00) on shares of Guardant Health in a research note on Wednesday, August 7th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Guardant Health has a consensus rating of “Buy” and an average target price of $111.80.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Featured Article: Understanding Options Trading
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.